Company profile
AYTU BIOPHARMA, INC
NASDAQ:AYTUBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ACIPHEX SPRINKLE | approved | — | 0 | — |
| KARBINAL ER | approved | — | 0 | — |
| PROSTASCINT | approved | — | 0 | — |
| ZOLPIMIST | approved | — | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07169162 | phase4 | withdrawn | 2019-05-01 | 2025-09-05 | Aytu BioPharma, Inc. | ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder |
| NCT05463679 | phase3 | suspended | 2025-01-01 | 2025-06-01 | Aytu BioPharma, Inc. | Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. |
FDA applications (4)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 022556 | 2013-03-28 | NDA | AYTU BIOSCIENCE INC | |||||
Loading… | ||||||||
| NDA 204736 | 2013-03-26 | NDA | AYTU BIOSCIENCE INC | |||||
Loading… | ||||||||
| NDA 022196 | 2008-12-19 | NDA | AYTU BIOSCIENCE INC | |||||
Loading… | ||||||||
| BLA 103608 | 1996-10-28 | BLA | AYTU BIOSCIENCE, INC. | |||||
Loading… | ||||||||